AI Article Synopsis
- Sustained Complete Response (SUS-CR) may serve as a better indicator for patient survival in multiple myeloma compared to just achieving Complete Response (CR).
- Data from Total Therapy 2 (TT2) involving 668 patients showed that SUS-CR significantly improved post-treatment survival when compared to not achieving CR or losing CR within three years.
- The findings were validated in additional studies and suggest that SUS-CR should be considered a primary endpoint in trials for high-risk multiple myeloma, regardless of other adverse factors.
Article Abstract
Background: Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma.
Methods: By using Total Therapy 2 (TT2) clinical outcome data in 668 patients, whether sustained CR (SUS-CR) was potentially a superior surrogate for survival than attaining CR status per se was evaluated.
Results: Compared with not achieving CR (NON-CR) and especially achieving and subsequently losing CR status (LOS-CR) within a 3-year landmark from treatment initiation, SUS-CR was associated with highly superior postlandmark survival (P < .0001). These results were validated in 231 untreated patients enrolled in the predecessor trial, TT1 (hazard ratio [HR] = 0.54, P = .013) and in 1103 previously treated patients on other transplant protocols (HR = 0.49; P < .001).
Conclusions: In all 3 trial settings the survival benefit of SUS-CR was independent of metaphase abnormalities as a dominant adverse parameter. Given its bleak prognosis despite high CR rates, SUS-CR should be evaluated as a primary trial endpoint in high-risk myeloma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.23546 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!